pillbase.ru

VIJOICE

Active substance: alpelisib

TABLET · ALPELISIB 50 mg/1

United StatesActive

Marketing holder: Novartis Pharmaceuticals Corporation

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 3
  • Piqray
    alpelisib
    EMEA/H/C/004804
    Novartis Europharm Limited
  • Vijoice
    alpelisib
    EMEA/H/C/005468
    Novartis Europharm Limited
  • Vijoice
    alpelisib
    EMEA/H/C/006539
    Novartis Europharm Limited
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-45ca-705a-b45d-4d6f1b01dc65,01a1208c-4872-7ee8-8493-f7ff4114b145,01a1208d-f7d5-7233-a954-12b143520885,01a1208e-03fa-7d22-a83e-5468b25312d4,01a1208f-7d3d-70e4-84ef-57227ed57c22;count=13 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
0078-1021
Registration status
Active
Dispensing
Prescription only
Route
ORAL
Sources
  • product · openFDA NDC · 0078-1021 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 0078-1021 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 0078-1021 · Verified 2026-10-09 · open in source